Fauna Bio

We’re excited to announce a strategic collaboration agreement with Eli Lilly and Company to apply Fauna's Convergence? artificial intelligence (AI) platform to support preclinical drug discovery efforts in #obesity. The two teams will collaborate to identify multiple drug targets. ?????? "We are very excited to enter into this collaboration with Lilly, which showcases the power of our Convergence? AI platform to rapidly identify novel targets for complex disease areas of high unmet need," said Ashley Zehnder, CEO & Co-Founder, Fauna Bio. "Lilly is a leader in obesity treatment, and our approach enables and accelerates discovery across different disease areas and modalities for our partners, who bring deep expertise in drug development." Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly, added: "Fauna Bio brings a unique approach to the discovery of novel targets for obesity. We look forward to working with the Fauna Bio team to realize the value of their platform and discover more effective treatments for patients with obesity." Read the release: ?????? https://lnkd.in/e8CtkrBb #drugdiscovery #biotech #AI #obesity

Our CEO Ashley Zehnder will be speaking tmr on the AI Bio panel at the Cerebral Valley AI Summit in SF. ???? The one-day summit features conversation with the brightest minds in AI and an opportunity for the people building the next generation of AI to meet each other. Sharing more info: https://lnkd.in/gEcdBtUZ

Our CEO Ashley Zehnder will be speaking on a #longevity panel next week at the San Francisco Bay Family Office & High Net Worth Annual Conference! ???? Beyond Lifespan: Harnessing Science and Capital for a Healthier Future This powerhouse panel brings together a pioneering founder, leading investor and professor, top scientist and community builder, and experienced and discerning high-net-worth consumer to reveal how cutting-edge tech and personalized wellness are reshaping longevity. We will explore turning advancements in health into generational assets while uncovering new opportunities to enhance your quality of life with direct insights. Panelists: Johannon Olson, RN/MBA, Chair, TIGER 21 Dr. Christin Glorioso, MD PHD, Co-Founder & CEO, NeuroAge Therapeutics Dr. Ronjon Nag, Adjunct Professor, Stanford Medicine; President, R42 Group Ashley Zehnder, Chief Executive Officer, Fauna Bio Mike Orsak, Founder Worldview Technology Partners More info here: ???? https://lnkd.in/eF5jSUsh

?? Ready to dive into the world of biotech innovation? Don’t miss the upcoming Innovation Showcase by California Life Sciences! This event will showcase groundbreaking startup pitches, offering a glimpse into the future of life sciences innovation. Attendees will also have the opportunity to network with industry leaders and connect with pioneering founders, investors, and partners who are shaping the future of healthcare and biotech. One highlight of the day will be Navigating the Road to Success – Founders’ Perspectives on Creating, Building, and Scaling Startups, featuring a powerhouse panel of former FAST Program alumni and CLS members sharing their real-world insights: ? Ashley Zehnder – CEO & Co-founder, Fauna Bio ? Jonathan Romanowsky – CBO & Co-founder, Inflammatix, Inc. ? Maria Soloveychik – CEO & Co-founder, SyntheX ? Shelley Force Aldred – CEO & Co-founder, Rondo Therapeutics ? Marco Lobba, Ph.D. – CEO & Co-founder, CatenaBio (Moderator) These founders will share their journeys and invaluable advice on creating, building, and scaling life sciences startups. This is your chance to gain firsthand insights and join in discussions with experts driving change across healthcare, diagnostics, therapeutics, and more. Join us at the Innovation Showcase for a day packed with learning, networking, and innovation! Register and Learn More: https://lnkd.in/gbUF7JrN #InnovationShowcase #LifeSciences #Biotech #Startups #FASTProgram #CLS #HealthcareInnovation #InnovationandEntrepreneurship

Our CEO Ashley Zehnder spoke with C&EN: Zehnder is a trained veterinarian with a PhD in oncology and cancer biology from Stanford University. She and her two cofounders came up with the idea for Fauna Bio when they were postdoctoral researchers at the university. They were mulling the idea of applying to a Stanford-associated accelerator when they met Laura Deming, cofounder and venture partner at an accelerator called age1. She offered them a spot. https://lnkd.in/eCJqjAWz

Insightful learnings shared on the application of technology and its impact on discovery and delivery across #biopharma. Thank you Kai Wucherpfennig?Dana-Farber Cancer Institute, Chandra Ramanathan Danaher Corporation, Ashley Zehnder Fauna Bio, Hanadie Yousef Juvena Therapeutics & Jason Cole SalioGen Therapeutics.

Ashley Zehnder, founder and CEO of Fauna Bio, discusses the types of insights that can be gleaned from the genetics of hibernating animals, the wide range of human health conditions that might be addressed with such an approach, and the company’s deal with Eli Lilly to apply its AI platform to discover new obesity drugs. https://lnkd.in/eQ6z3B7E

Thanks Daniel Levine for speaking with our CEO Ashley Zehnder for your podcast. ???? Hibernation is not just a matter of deep sleep. Animals that hibernate are able to do so without suffering damage to tissue and muscle. Understanding the biology of hibernation can unlock potential insights into obesity, heart attack and stroke, muscle atrophy, neuroprotection, and longevity. ?????? Fauna Bio is studying genomic data from so-called "extreme mammals" and applying its proprietary AI platform to perform comparative genetic analysis to find gene-disease links and leverage millions of years of evolutionary adaptations to identify new therapeutic opportunities for human health. We spoke to Ashley Zehnder, founder and CEO of Fauna Bio, about the types of insights that can be gleaned from the genetics of hibernating animals, the wide range of human health conditions that might be addressed with such an approach, and the company’s deal with Eli Lilly to apply its AI platform to discover new obesity drugs. Listen and tune in here: ???? https://lnkd.in/eQ6z3B7E

Our CEO Ashley Zehnder will be speaking on a BIO Investor Forum panel on Tuesday, Oct 15 at 1 pm PT: “Standing Out from the Crowd: How to Capture Investor Attention in Competitive Fields.” In a highly competitive landscape, closing your next financing round or inking a partnership with big pharma requires that you effectively capture attention then clearly demonstrate your value proposition. Moderator: Jason Spark, President, Biotech - Inizio Evoke Speakers Dr. Judy Chou - PhD, President and CEO - AltruBio Inc. Ashley Zehnder - PhD, Founder and CEO - Fauna Bio Dana Watt, PhD - PhD, Partner - Breakout Ventures Jayson Dallas - MD, PhD, CEO - Rivus Pharmaceuticals Sharing the full agenda: https://lnkd.in/dT3zhgkY

Did you know that the plant and animal kingdom can help scientists study areas like extreme metabolic changes, obesity resistance, and muscle preservation? ?? All of this can lead to the discovery of novel therapeutic targets and the development of drugs that mimic these natural protective mechanisms. Additionally, substances derived from animals, such as snake venoms, can also lead to the development of therapeutics to treat diseases such as cancer. ?? There are now several biotech companies working in this particular area. ???? Read our latest article to learn about 5 biomimicry companies! ?? https://lnkd.in/ewdFjp8Y #biomimicry #therapeuticdiscovery #obesityresistance #cancertherapies #biotechinnovation #biomimicryinmedicine Bioxodes | Celtic Biotech Ltd | ExeVir | Fauna Bio | Isogenica | Soricimed Biopharma Inc.